ORKA MEXC RealStocks
Own real ORKA shares through MEXC's regulated brokerage partner.
Suitable for long-term holding.
- Own the actual shares
- Receive dividends and voting rights
- Buy fractional shares starting at $1
Last updated: 2026-11-19 08:30:40. Prices reflect the latest closing data and will resume updating on the next trading day. Stock price data is sourced from Massive.
Oruka Therapeutics, Inc. (ORKA) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $95.66, with a market capitalization of $6.53B and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $25.23 to $115.52. This page covers its latest market performance, valuation, price trends and company information.
$6.53B | |
$96.31 | |
$100.04 | |
$95.14 | |
$96.32 | |
415.49K | |
949.48K | |
-- | |
$115.52 | |
$25.23 | |
-- | |
2026-09-30 |
Oruka Therapeutics, Inc. (ORKA) last closed at $95.66 as of 2026-11-19 00:31:00, down 0.72% ($0.69) from the previous close of $96.32.
During the latest regular trading session, ORKA traded between $95.14 and $100.04, with a volume of 415.49K shares. The closing price was near the lower end and near the upper end of its 52-week range.
Over the past seven days, Oruka Therapeutics, Inc. (ORKA) moved from $109.50 to $95.66, representing a decline of 12.64% ($13.84).
The stock traded between $95.05 and $113.24 during the period. The latest price is near the lower end of the 7-day range, indicating strong downward.
The average daily volume was 1.08 million shares, up versus the previous seven-day period, indicating higher trading activity.
Position in Range: 78.0%
ORKA is currently trading at $95.66, placing it 78.0% of the way from its 52-week low of $25.23 to its 52-week high of $115.52. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Oruka Therapeutics Inc a clinical-stage biopharmaceutical company focused on developing novel monoclonal antibody therapeutics for psoriasis (PsO) and other inflammatory and immunology (I&I) indications. Its programs are to treat and potentially modify disease by targeting mechanisms with efficacy and safety involved in disease pathology and the activity of pathogenic tissue-resident memory T cells (TRMs). Its program, ORKA-001, is designed to target the p19 subunit of interleukin-23 (IL-23p19) for the treatment of PsO. Its co-lead program, ORKA-002, is designed to target interleukin-17A and interleukin-17F (IL-17A/F) for the treatment of PsO, hidradenitis suppurativa (HS), psoriatic arthritis (PsA), and other conditions.
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 68 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Oruka Therapeutics, Inc. (ORKA) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.
Stock prices and market data on this page, including price changes and market status, are provided by Massive and other third-party news and data platforms. Market data may be delayed and may differ from prices on other platforms or the prices at which trades are executed on MEXC. MEXC does not guarantee the accuracy, completeness, or timeliness of third-party data. MEXC offers trading products related to ORKA, including Stocks, Tokenized Stocks, and Stock Futures.
The stock price information displayed on this page is provided for reference purposes only and may be delayed or differ from real-time market data. Prices, charts, and related metrics do not constitute investment advice and should not be relied upon for trading or investment decisions. MEXC is not responsible for any losses incurred based on the stock price information provided on this page. Please refer to official market sources or consult licensed financial professionals before making any investment decisions.
Estimate the value between ORKA shares and USD.
ORKA Shares to USD
1.00 ORKA shares = 95.661 USD
Calculations are estimates based on the latest available price and are for reference only.